Shilpa Medicare gains as its arm gets CEP from EDQM for API, Nifedipine
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Shilpa Medicare is currently trading at Rs. 892.30, up by 12.40 points or 1.41% from its previous closing of Rs. 879.90 on the BSE.
The scrip opened at Rs. 900.45 and has touched a high and low of Rs. 906.40 and Rs. 864.55 respectively. So far 11825 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 959.95 on 18-Sep-2024 and a 52 week low of Rs. 313.55 on 10-Jan-2024.
Last one week high and low of the scrip stood at Rs. 917.20 and Rs. 816.00 respectively. The current market cap of the company is Rs. 8500.96 crore.
The promoters holding in the company stood at 44.33%, while Institutions and Non-Institutions held 17.76% and 37.90% respectively.
Shilpa Medicare’s 100% subsidiary -- Shilpa Pharma Lifesciences has received certificate of suitability (CEP) from EDQM (European Directorate for the Quality of Medicines & Healthcare) for API, Nifedipine.
Nifedipine is in a class of medications called calcium-channel blockers in the dihydropyridine subclass. Nifedipine is used as an antihypertensive and as an anti-anginal medication. It lowers blood pressure by relaxing the blood vessels so the heart does not have to pump as hard. It controls chest pain by increasing the supply of blood and oxygen to the heart
The CEP showcases its expertise and commitment to quality-oriented development and commercial production, which meets the expectations of global quality standards.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
